Abraham Morgentaler, MD, FACS

Abraham Morgentaler, MD, FACS

Men's Health Boston

Boston, MA

Abraham Morgentaler, MD was born in Montreal, Canada. He graduated from Harvard College in 1978, and Harvard Medical School in 1982. Dr. Morgentaler completed his residency in 1988 from the Harvard Program in Urology, and then joined the faculty of Beth Israel Deaconess Medical Center and Harvard Medical School. He is currently an Associate Clinical Professor of Surgery (Urology). In 1999 Dr. Morgentaler founded Men's Health Boston, the first center in the US to focus on sexual, reproductive, and hormonal health for men. Dr. Morgentaler was the recipient of the New Investigator Award in 1994 granted by the American Foundation of Urological Disease. Dr. Morgentaler is an international authority on men’s health and a pioneer in the treatment of testosterone deficiency in men. Dr. Morgentaler’s research is credited for reversing the decades-old belief that testosterone therapy is risky for prostate cancer. Dr. Morgentaler has published over 120 scientific articles on testosterone, prostate cancer, male sexual dysfunction, and male infertility. His work has appeared in The New England Journal of Medicine, The Lancet, The Journal of the American Medical Association, Cancer, and The American Journal of Medicine. He is the author of the recently published book, Why Men Fake It: The Totally Unexpected Truth About Men and Sex, which has been widely hailed as a groundbreaking exploration of male sexuality. Dr. Morgentaler’s other books include Testosterone For Life: Recharge Your Vitality, Sex Drive, Muscle Mass, and Overall Health, and The Viagra Myth: The Surprising Impact on Love and Relationships.

Articles by Abraham Morgentaler, MD, FACS

Disease Flare with LHRH Agonists is a Myth

Abraham Morgentaler, MD, FACS, describes the phenomenon of testosterone flare following prostate cancer treatment with luteinizing hormone-releasing hormone (LHRH) agonists and argues that this flare does not necessarily cause disease progression. He also discusses the effects of testosterone therapy in patients with untreated prostate cancer.

Read More

Join the GRU Community

- Why Join? -